BridgeBio Pharma Earnings
NASDAQ: BBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Next earnings date
Wed, Nov 4, 2026
Fiscal period
Sep/2026
EPS estimate
$-0.67
BridgeBio Pharma earnings summary
BridgeBio Pharma is scheduled to report Sep/2026 earnings on Nov 4, 2026, with analysts expecting EPS of $-0.67. In its most recent report on Aug 10, 2026 (Q2 2026), BBIO posted EPS of $-0.78. Revenue for the quarter was $243.7 million.
Across the last 16 reports, BBIO shares moved an average of 5.1% (in either direction) in the first trading session after results, rising 5 times and falling 11 times.
Summary generated from market data by MetaCap's automated system. Methodology
BBIO earnings history
| Report date | EPS est. | EPS actual | Surprise | Price reaction |
|---|---|---|---|---|
| Aug 10, 2026 | — | $-0.78 | — | +2.1% |
| May 7, 2026 | — | $-0.84 | — | -1.9% |
| Feb 24, 2026 | — | $-1.00 | — | -1.7% |
| Oct 29, 2025 | — | $-0.95 | — | -1.3% |
| Aug 5, 2025 | — | $-0.95 | — | +10.2% |
| Apr 29, 2025 | — | $-0.88 | — | -11.4% |
| Feb 20, 2025 | — | $-1.43 | — | -5.3% |
| Nov 12, 2024 | — | $-0.86 | — | -1.3% |
| Aug 1, 2024 | — | $-0.39 | — | -6.7% |
| May 2, 2024 | — | $-0.20 | — | +4.6% |
| Feb 22, 2024 | — | $-0.97 | — | +4.8% |
| Nov 2, 2023 | — | $-1.08 | — | -6.0% |
| Aug 3, 2023 | — | $-0.98 | — | -0.6% |
| May 4, 2023 | — | $-0.92 | — | -1.0% |
| Feb 23, 2023 | — | $-0.91 | — | -6.7% |
| Nov 3, 2022 | — | $-0.93 | — | +15.4% |
Surprise compares reported EPS with the consensus estimate. Price reaction is the close-to-close move in the first session after the report. Learn about the earnings surprise.